Sarepta Therapeutics (NASDAQ:SRPT) Given New $13.00 Price Target at Citigroup

Key Points

• Citigroup raised its price target on Sarepta to $13 from $9 but kept a "sell" rating, with the new target implying roughly a 40% downside from the stock's current price.
• The analyst landscape is mixed: the consensus rating is Hold with an average price target of $32.30 (nine Buys, 13 Holds, six Sells), while individual targets range from about $20 to $37.
• Sarepta reported a large EPS miss (loss of $3.58 vs. est. −$0.87) despite $442.9M revenue (down 32.7% YoY); recent positive early Phase 1/2 siRNA data and heavy call buying have driven rallies but valuation and execution risks remain.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price raised by research analysts at Citigroup from $9.00 to $13.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "sell" rating on the biotechnology company's stock. Citigroup's price objective would suggest a potential downside of 40.40% from the stock's current price.

A number of other equities analysts have also issued reports on the stock. Oppenheimer reiterated an "outperform" rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Jefferies Financial Group restated a "buy" rating and set a $30.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Wedbush decreased their price objective on shares of Sarepta Therapeutics from $34.00 to $29.00 and set an "outperform" rating for the company in a report on Monday, March 2nd. Wall Street Zen upgraded shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Finally, Barclays started coverage on Sarepta Therapeutics in a report on Wednesday, January 28th. They set an "equal weight" rating and a $20.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $32.30.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $1.96 during trading on Thursday, reaching $21.81. 2,616,318 shares of the company's stock were exchanged, compared to its average volume of 2,911,369. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $73.95. The company's fifty day moving average price is $18.70 and its 200-day moving average price is $19.96. The firm has a market cap of $2.29 billion, a PE ratio of -2.59, a P/E/G ratio of 0.28 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same period last year, the business posted $1.90 earnings per share. Sarepta Therapeutics's revenue for the quarter was down 32.7% on a year-over-year basis. On average, research analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director owned 1,765 shares of the company's stock, valued at $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. CWM LLC lifted its position in shares of Sarepta Therapeutics by 4,033.3% during the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company's stock valued at $1,401,000 after acquiring an additional 70,946 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company's stock worth $38,208,000 after acquiring an additional 740,360 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 309.1% in the 2nd quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company's stock worth $11,542,000 after acquiring an additional 510,000 shares during the last quarter. Edgestream Partners L.P. grew its holdings in shares of Sarepta Therapeutics by 870.3% in the 2nd quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company's stock worth $1,419,000 after acquiring an additional 74,427 shares during the last quarter. Finally, Boxer Capital Management LLC raised its position in shares of Sarepta Therapeutics by 900.0% during the third quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company's stock worth $4,818,000 after purchasing an additional 225,000 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA data showed dose-dependent muscle exposure, early biomarker effects and favorable tolerability for SRP-1001 (FSHD1) and SRP-1003 (DM1), which is the primary catalyst for the rally. Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
• Positive Sentiment: Analyst reactions and estimate updates amplified the move: coverage reports cite a meaningful price-target lift and upward estimate revisions after the data, supporting further upside expectations. Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
• Positive Sentiment: Heavy bullish options activity — a large uptick in call buying — indicates speculative and leveraged positioning by traders anticipating further upside or volatility tied to the program readouts. (Internal trade reporting)
• Neutral Sentiment: Some market-wide tailwinds (lower VIX / broader equity gains) provided a constructive backdrop for biotech rebounds, so part of the move reflects broader risk-on flows rather than company-specific fundamentals alone. The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil
• Neutral Sentiment: Short-interest reports in some feeds appear inconsistent (calls out “0 shares” / NaN changes), so short-covering signals are unclear from public short data and should be treated cautiously.
• Negative Sentiment: Not all analysts are convinced — at least one firm reaffirmed an “underperform” stance and some coverage highlights valuation and execution risk despite promising early data, which could cap upside until larger/more definitive trials and regulatory paths are clearer. Benzinga: Needham Reaffirms Underperform

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.